Brokerages Set HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Target Price at $16.88

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) has earned an average recommendation of “Hold” from the five analysts that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $16.8750.

Several equities research analysts recently weighed in on HCM shares. Weiss Ratings cut shares of HUTCHMED from a “hold (c)” rating to a “hold (c-)” rating in a research note on Friday, May 1st. Bank of America cut their price target on shares of HUTCHMED from $21.00 to $20.00 and set a “buy” rating for the company in a research note on Tuesday, March 10th. Finally, Wall Street Zen cut shares of HUTCHMED from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HCM. Blue Trust Inc. lifted its stake in HUTCHMED by 131.5% during the fourth quarter. Blue Trust Inc. now owns 7,708 shares of the company’s stock worth $103,000 after purchasing an additional 4,378 shares during the period. Ameriprise Financial Inc. boosted its stake in shares of HUTCHMED by 4.7% in the 2nd quarter. Ameriprise Financial Inc. now owns 15,519 shares of the company’s stock valued at $234,000 after purchasing an additional 698 shares in the last quarter. Vanguard Personalized Indexing Management LLC boosted its stake in shares of HUTCHMED by 12.1% in the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 17,363 shares of the company’s stock valued at $273,000 after purchasing an additional 1,873 shares in the last quarter. Bank of America Corp DE boosted its stake in shares of HUTCHMED by 17.3% in the 2nd quarter. Bank of America Corp DE now owns 20,582 shares of the company’s stock valued at $310,000 after purchasing an additional 3,035 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in shares of HUTCHMED by 34.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 21,721 shares of the company’s stock valued at $342,000 after purchasing an additional 5,538 shares in the last quarter. Institutional investors own 8.82% of the company’s stock.

HUTCHMED Stock Performance

NASDAQ HCM opened at $11.91 on Friday. The company has a current ratio of 4.96, a quick ratio of 4.83 and a debt-to-equity ratio of 0.05. The firm has a 50-day simple moving average of $14.10 and a 200 day simple moving average of $14.36. HUTCHMED has a twelve month low of $11.81 and a twelve month high of $19.50.

HUTCHMED (NASDAQ:HCM) last released its earnings results on Friday, March 6th. The company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $2.50 by ($2.49). The company had revenue of $135.42 million for the quarter, compared to analyst estimates of $290.50 million. As a group, research analysts forecast that HUTCHMED will post 0.41 EPS for the current fiscal year.

HUTCHMED Company Profile

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.